Pfizer Agrees to Buy Seagen for $43 Billion.

New York-based Pfizer has been looking for acquisitions to help it offset an expected sales loss of $17 billion by 2030 as some top-selling drugs like blood thinner Eliquis and breast-cancer drug Ibrance lose patent protection in the next several years. Keywords: wsjhealth; Biotechnology Services; Pharmaceuticals; Cancer Drugs; Healthcare/Life Sciences; Biopharmaceuticals; Specialized Drugs/Medications; Ownership Changes; Acquisitions/Mergers/Shareholdings; Anti-Competition Issues EN wsjhealth Biotechnology Services Pharmaceuticals Cancer Drugs Healthcare/Life Sciences Biopharmaceuticals Specialized Drugs/Medications Ownership Changes Acquisitions/Mergers/Shareholdings Anti-Competition Issues N.PAG N.PAG 1 03/16/23 20230314 NES 230314 The drugmaker would pay $229 a share in cash for the biotech cancer specialist Graph: Pfizer has been looking for acquisitions to help it offset an aging drug lineup. The drugs could become one of the next big segments of the $375 billion worldwide cancer-drugs market, accounting for $31 billion in sales in 2028, drug-market-research firm Evaluate estimates. [Extracted from the article]